RECRUITING

A Novel Non-Pharmacological Treatment of Diabetic Neuropathy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of the proposed work is to develop non-pharmacological interventions for diabetic peripheral neuropathy (DPN), to improve quality of life of individuals with diabetes, and reduce the prevalence of opiate prescription, sensation loss, falls, and deaths caused by DPN. To this end, the proposed study will investigate and determine the feasibility of the non-pharmacological intervention device. The feasibility study involves 16 participants, split evenly between pre-neuropathic diabetic and neuropathic diabetic participants. During the study, each group will receive the same 45-minute intervention on 10 days spread over no more than 14 days total. Feasibility will be determined by change in pain assessed before and after intervention.

Official Title

A Novel Non-Pharmacological Treatment of Diabetic Neuropathy

Quick Facts

Study Start:2023-03-22
Study Completion:2025-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05414968

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * diagnosis of type 2 diabetes for at least 5 years
  2. * lab histories that verify participant's control or lack of blood sugars dating back for a period of 1-5 years
  1. * other diseases or impairments that could affect results (vascular disease verified from medical history
  2. * ankle-brachial index (ABI) of 0.9 or less

Contacts and Locations

Study Contact

Chad G Rose, PhD
CONTACT
8655672205
chadgrose@auburn.edu
Michael E Zabala, PhD
CONTACT
(334) 844-4916
zabalme@auburn.edu

Principal Investigator

Chad G Rose, PhD
PRINCIPAL_INVESTIGATOR
Auburn University

Study Locations (Sites)

Auburn University
Auburn, Alabama, 36849
United States

Collaborators and Investigators

Sponsor: Auburn University

  • Chad G Rose, PhD, PRINCIPAL_INVESTIGATOR, Auburn University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-22
Study Completion Date2025-06-01

Study Record Updates

Study Start Date2023-03-22
Study Completion Date2025-06-01

Terms related to this study

Keywords Provided by Researchers

  • nonpharmacological intervention

Additional Relevant MeSH Terms

  • Diabetic Peripheral Neuropathy